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Age related macular degeneration (AMD) is the leading cause of blindness among people
aged 50 and over. Retinal deposition of amyloid-β (Aβ) aggregates in AMD patients
has suggested a potential link between AMD and Alzheimer’s disease (AD). We have
evaluated the differential retinal expression profile of miRNAs in a rat model of AMD
elicited by Aβ. A serum profile of miRNAs in AMD patients has been also assessed using
single TaqMan assay. Analysis of retina from rats intravitreally injected with Aβ revealed
that miR-27a, miR-146a, and miR-155 were up-regulated in comparison to control rats.
Seven miRNA (miR-9, miR-23a, miR-27a, miR-34a, miR-126, miR-146a, and miR-155)
have been found to be dysregulated in serum of AMD patients in comparison to control
group. Analysis of pathways has revealed that dysregulated miRNAs, both in the AMD
animal model and in AMD patients, can target genes regulating pathways linked to
neurodegeneration and inflammation, reinforcing the hypothesis that AMD is a protein
misfolding disease similar to AD. In fact, miR-9, miR-23a, miR-27a, miR-34a, miR-146a,
miR-155 have been found to be dysregulated both in AMD and AD. In conclusion,
we suggest that miR-9, miR-23a, miR-27a, miR-34a, miR-146a, miR-155 represent
potential biomarkers and new pharmacological targets for AMD.
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INTRODUCTION
Age related macular degeneration (AMD) is a common eye disease and the leading cause of
blindness among people aged 50 years and older. AMD exists in dry and wet forms, the first is
much more common than wet. Dry AMD is characterized by cellular debris, identified as drusen
bodies, that accumulate between choroid and retina. Drusen are hallmarks of dry AMD and contain
a variety of constituents, among of others, amyloid-β (Aβ) deposit. The wet form bears abnormal
growth of choroidal blood vessels leading to detachment of retina along with vascular leakage
and related retinal edema. AMD is listed by the World Health Organization (WHO) among the
“priority eye diseases.” Besides a series of phase II/III clinical trials, up to now there is no approved
treatment for dry AMD, and treatment for wet AMD is not definitive. In general, wet AMD patients
experience rapid visual aberration with progression of the disease, due to vascular leakage, whereas
Romano et al. miRNAs in Age-Related Macular Degeneration
dry AMD is often asymptomatic (Yorston, 2006; Pascolini
and Mariotti, 2012). Therefore, validated microinvasive
biomarkers of AMD are desirable in order to diagnose and
prevent irreversible macular damage. Several single nucleotide
polymorphisms (SNPs) and their association to AMD have
been investigated and validated: such SNPs involve complement
proteins (Gemenetzi and Lotery, 2016). Furthermore, ocular
inflammatory processes have been recognized as a hallmark
of AMD (Stanton and Wright, 2014; Romano et al., 2015);
inflammation being a response to molecules coming from
dysfunctional retinal pigment epithelium (RPE), such as
lipofuscin, Aβ, carboxyethyl pyrrole. Along to these molecules
found in drusen of AMD patients, C-reactive protein was
found in serum of patients with severe AMD (Seddon et al.,
2004, 2010; Vine et al., 2005); however, other studies have not
confirmed significant increased levels of C-reactive protein in
serum of AMD patients in comparison to healthy control (Dasch
et al., 2005; McGwin et al., 2005). Therefore, identification and
validation of serum, minimally-invasive, biomarkers of AMD
are still challenging. In this perspective, differential expression
of miRNAs in serum or plasma represents a potential approach
to identify novel biomarkers and pharmacological targets of
AMD as suggested by Berber et al. in their compelling review
(Berber et al., 2017). MiRNAs are short, approximately 22-mer,
non-coding RNA molecules bearing important regulatory
functions, such as post-transcriptional regulation of gene
expression (Bartel, 2004). Cells can secrete miRNAs that can
be found stably in serum, plasma and many other biological
fluids (Mitchell et al., 2008; Weber et al., 2010). Extracellular
miRNAs are stable due to association to cell-derived nanovesicles
(e.g., exosomes), RNA-binding proteins (e.g., Argonaute 2)
or high density lipoproteins HDL (Creemers et al., 2012).
Recently, miRNAs were analyzed in vitreous and plasma of
exudative AMD patients, by means of non-biased miRNA
arrays and validation with qPCR; miRNA-146a was found to be
significantly up-regulated both in vitreous and plasma of AMD
patients (Ménard et al., 2016; Berber et al., 2017). Interestingly,
miRNA-146a is found also down-regulated in cerebrospinal
fluid (CSF) of AD patients (Kiko et al., 2014; Müller et al., 2014;
Denk et al., 2015). AMD is a complex multifactorial disease; a
pathogenic mechanism common to Alzheimer’s disease (AD)
was postulated on the basis of Aβ deposition in drusen of AMD
patients (Johnson et al., 2001; Dentchev et al., 2003; Isas et al.,
2010; Romano et al., 2015; Fisichella et al., 2016). Based on this
ground, several experimental models of retinal degeneration
attempted to induce retinal damage and mimic AMD by using
Aβ. In vitro, stimulation of retinal pigmented epithelium with
Aβ induces expression of VEGFA (Matsui et al., 2015) and
inflammatory cytokines (Liu et al., 2012, 2013; Cao et al., 2013).
In vivo, injection of Aβ in the posterior chamber of animal eye
induces inflammation (Howlett et al., 2011; Liu et al., 2013),
apoptosis (Fisichella et al., 2016), and blood-retinal barrier
(BRB) breakdown (Anderson et al., 2008). Because these data
suggest that some common mechanism may link AMD and AD,
we tested the hypothesis that the profile of miRNA expression
in an animal model of Aβ-induced retinal damage and in
patients affected by AMD might show some similarities. In the
perspective of a translational approach, analysis of miRNAs may
provide not only new insights in the pathogenic mechanisms
of AMD co-shared with AD, but also novel biomarkers and
pharmacological targets.
METHODS
Literature Search and Selection of miRNAs
to Be Analyzed
Extensive literature search has been carried out in order to
select miRNAs (Table 1) similarly dysregulated in AMD and AD.
Dysregulation of miRNAs in AMD and AD has been evaluated
by accessing to miR2Disease and Human microRNA Disease
Database (HMDD) and through literature search (Romano et al.,
2015).
AMD Animal Model
All experiments followed the guidelines set by the Association for
Research in Vision and Ophthalmology Resolution on Treatment
of Animals in Research; the experimental protocol was approved
by the Institutional Animal Care and Use Committee (IACUC)
at University of Catania.
Human amyloid-β1−42 (Aβ) oligomers were freshly prepared
accordingly to the following protocol:
• Reconstitution of lyophilized Aβ trifluoroacetic salt
(Invitrogen, Carlsbad, CA, USA) at a concentration 1mM in
100% 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP);
• Incubation of solution at room temperature for 1 h and then
sonication for 10min in water bath sonicator;
• Removing of HIFP under gentle stream of Argon;
• Storage: vials, containing peptide Parafilm©-sealed at−20◦C;
• Solubilization of the peptide in anhydrous dimethyl-sulfoxide
(DMSO) at 5mM final Aβ concentration;
• Dilution with sterile PBS pH 7.4, at 100µM final Aβ
concentration, and incubation for 24 h at 4◦C.
This protocol is in accordance with the protocol used by several
groups (Lambert et al., 2001; Dahlgren et al., 2002; Barghorn
et al., 2005; Guo et al., 2007) and to the original protocol
developed by Klein and co-authors (Klein et al., 2001).
Male Sprague-Dawley rats (250–300 g) were purchased from
Harlan (Udine, Italy). The animals were fed with standard
laboratory chow and allowed free access to water in an air
controlled room with a 12-h light/12-h dark cycle. The animals
were randomly divided in two experimental groups (n = 10):
(1) control group, received intravitreal injection of 2µl of
sterile PBS pH 7.2, DMSO 2%; (2) treated group, received
intravitreal injection of 0.2 nmol of Aβ (2µl of Aβ oligomer
solution). Animals were anesthetized by intravenous injection
of 5mg/kg Zoletil (2.5mg/kg tiletamine•HCl, and 2.5mg/kg
zolazepam•HCl; Zoletil, Virbac,Milano, Italy) and 1 drop of local
anesthetic (oxybuprocaine 0.4%; Novesina, Novartis, Origgio,
Italy) has been administered to the eye, prior intravitreal injection
(Fisichella et al., 2016). After 72 h the animals were killed and
blood and retina samples collected; time slot was chosen on the
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TABLE 1 | Selection of miRNAs potentially involved in AD and AMD.
miRNA Reference AMD Reference AD
miR-9 Kutty et al., 2010; Lukiw et al., 2012 databases
miR-21 Ertekin et al., 2014 databases
miR-23a Kutty et al., 2010; Lin et al., 2011 Lau et al., 2013; Galimberti et al., 2014
miR-24 Ertekin et al., 2014 Lugli et al., 2015
miR-27a Wang et al., 2012 Maes et al., 2009; Sala Frigerio et al., 2013
miR-30b Haque et al., 2012 Schonrock et al., 2010
miR-34a Hou et al., 2013; Smit-McBride et al., 2014 databases
miR-125b Arora et al., 2010; Lukiw et al., 2012 databases
miR-126 Bai et al., 2011 Sonntag et al., 2012
miR-146a Lukiw et al., 2012; Kutty et al., 2013; Ménard et al., 2016; Berber et al., 2017 databases
miR-146b Kutty et al., 2013 databases
miR-155 Saxena et al., 2015; Yan et al., 2015; Zhuang et al., 2015; Berber et al., 2017 Guedes et al., 2014
miR-210 Devlin et al., 2011; Wang et al., 2012; Szemraj et al., 2015 databases
Databases: miR2Disease and Human microRNA Disease Database (HMDD).
basis of previously findings reporting early retinal damage 72 h
after intravitreal administration of Aβ (Guo et al., 2007).
Clinical Study
The study adhered to the tenets of the Declaration of Helsinki
and was approved by the Local Ethics Research Committee
(Comitato Etico Catania1). Before starting the study, written
informed consent was obtained from all patients. Eleven patients
(average age 70 ± 6) were enrolled between May and July 2014
at the Retina Division of the Eye Institute of the University
of Catania (Italy); active choroidal neovascularization (CNV)
secondary to neovascular AMD was confirmed by fluorescein
angiography. The following exclusion criteria were applied: active
uveitis or ocular infection, presence of any retinopathy other
than AMD, any ocular surgery within the 60 days prior to
enrollment. Patients with cardiovascular disease, including a
history of stroke or myocardial infarction <3 months prior to
screening, uncontrolled blood pressure (defined as systolic value
of >160mmHg or diastolic value of >100mmHg at screening
at screening), diabetes mellitus, history of cancer were also
excluded. For each patient with neovascular AMD, a healthy
subject was enrolled as control; the control healthy subject
matched the AMD patient in terms of age and sex, fulfilling the
inclusion and exclusion criteria.
All enrolled subjects underwent fasting venous blood
sampling. Blood samples were obtained by vein puncture using
sterile and dry vacutainer tubes. Samples were centrifuged for
serum isolation within 2 h from withdrawal. Whole blood was
incubated for 30min at 20◦C before being centrifuged at 3,000
rpm for 15min at 4◦C. Serum was divided into aliquots and
stored at−80◦C until analysis.
RNA Isolation from Serum and Retina
Human and rat serum samples were centrifuged at 2,000 rpm
for 10min to pellet circulating cells and/or debris. MiRNAs
were extracted from 400µl serum samples by using Qiagen
miRNeasy mini kit (Qiagen, Hilden, Germany), according to
Qiagen supplementary protocol for purification of small RNAs
from serum and plasma, and finally eluted in 40µl of elution
buffer. Total RNA, from rat retina samples, was purified by using
TRIzol R© reagent (ThermoFisher Scientific, Boston, MA, USA),
according to the manufacturer’s instructions. Quantification of
RNAs was carried out by fluorometry and spectrophotometry.
miRNA Profiling by Taqman Assay
We carried out RNA retro-transcription by TaqMan R©
MicroRNA Reverse Transcription Kit (ThermoFisher
Scientific); amplification was performed by Real Time PCR
with TaqMan probes (ThermoFisher Scientific), according to
the manufacturer’s instructions. We used miR-320a as reference
gene for normalization of human serum samples (Ragusa et al.,
2015), U6 and miR-16 for rat serum and retina samples (Tea
et al., 2013). Real Time PCRs was carried out on a 7,900 HT
Fast Real Time PCR System (Applied Biosystems, Monza, Italy).
Expression fold changes were calculated by the 2−11Ct method
(Livak and Schmittgen, 2001).
Bioinformatic Analysis of Biochemical
Pathways
The probability of association between miRNAs and KEGG
pathways was calculated through the web server DIANA-
miRPath 3.0 (Romano et al., 2015), by using the miRtarbase v7
algorithm. The following groups of miRNAs were analyzed:
(a) miR-27a, miR-146a, miR-155
(b) miR-9, miR-23a, miR-27a, miR-34a, miR-126,miR-146a,
miR-155
(c) miR-155
Statistical Analysis
GraphPad Prism (version 4.0; GraphPad Software, San Diego,
CA, USA) was used for statistical analysis and graphical
representation of miRNA differential expression data. Data sets
were examined by one-way analysis of variance (ANOVA).
Student’s T-test was used for comparison between two groups;
p< 0.05 were considered statistically significant.
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RESULTS
Dysregulation of miRNAs in AMD Rat
Model
We analyzed the expression of 13 miRNAs (Table 1), in retina
extracts from Sprague Dawley rats subjected to intravitreal
injection of Aβ oligomers. This in vivo model of AMD has been
used on the basis of previous reports showing the presence of
Aβ deposition in drusen bodies of AMD patients (Seddon et al.,
2004, 2010; Vine et al., 2005; Fisichella et al., 2016). Intravitreal
injection of Aβ induced the up-regulation of three miRNAs in rat
retina: miR-27a, miR-146a, and miR-155 (Table 2 and Figure 1).
Furthermore, miR-155 was down-regulated in serum of Aβ-
injected rats in comparison to controls (fold change −4.76; p =
0.029).
Dysregulation of miRNAs in Patients with
AMD
We analyzed the same 13 miRNA species also in serum of AMD
patients (Table 3). Dysregulation of 7 miRNAs (Table 3 and
Figure 2), out of 13 tested, was found in serum of AMD patients
in comparison to serum of control group. In particular, up-
regulation of miR-9, miR-23a, miR-27a, miR-34a, miR-126, and
miR-146a was found in serum of AMD patients. On the contrary,
miR-155 was down-regulated, similarly to what found in serum
of rats subjected to intravitreal injection of Aβ. Table 3 shows
the expression profile of miRNAs in serum of AMD patients.
Figure 2 reports box-plots of six miRNAs associated to both
AMD and AD.
Bioinformatics Analysis of Biochemical
Pathways Associated to miRNAs
Biochemical pathways potentially regulated by miRNAs
differentially expressed in retina of Aβ-injected rats (Figure 3
and Table 4A) and in serum of AMD patients (Figure 4 and
Table 4B) have been identified through the web server DIANA-
miRPath v.3. MiR-27a, miR-146a, and miR-155 (Figure 3 and
Table 4A), which were up-regulated in retina of Aβ-injected
rats, top scored as associated to TGF-β (p = 1 E-10) and prion
diseases (p = 2 E-11) pathways. MiR-27a, miR-146a, and miR-
155 have been reported to be associated to the inflammatory
pathways mTOR, TNFα, HIF signaling, and NF-κB (Romano
et al., 2015). Interestingly, apoptosis (p = 4 E-3), PI3K-AKT (p
= 1 E-2), and p53 pathways (p = 2 E-2) resulted as potentially
associated to the miRNAs differentially expressed in the retina
of AMD animal model. These results are also consistent with
our previous data (Fisichella et al., 2016) showing a deficit of
TGF-β signaling in the retina of Aβ injected rats, counteracted
by TGF-β1 co-administration. Furthermore, regulation of prion
diseases pathway by miR-27a, miR-146a, and miR-155, reinforces
the hypothesis that AMD can be a protein misfolding disease,
such as AD, due to deposition of Aβ oligomers in drusen bodies.
The potential link between AMD and AD is also in line with the
deregulation of insulin receptor signaling by miR-27a, miR-146a,
and miR-155 (Giuffrida et al., 2012; Gontier et al., 2015; Takach
et al., 2015; Han et al., 2016; Sajan et al., 2016; Table 4A). The set
of miRNAs differentially expressed in AMD patients can regulate
TABLE 2 | Differential expression of miRNAs, reported as fold change (FC),
in retina obtained from rats injected with Aβ vs. control group.
miRNA P-value
miR-16
p-value
snU6
FC miR-16 FC snU6
miR-9 0.059 0.051
miR-21 0.29 0.081
miR-23a 0.041 0.067
miR-24 0.199 0.161
miR-27a 0.046 0.012 2.47 2.75
miR-30b 0.94 0.957
miR-34a 0.257 0.126
miR-125b 0.45 0.604
miR-126 0.597 0.657
miR-146a 0.008 0.006 2.59 2.81
miR-146b 0.096 0.154
miR-155 0.003 0.002 3.09 3.95
miR-210 0.364 0.917
the same pathways of miRNAs dysregulated in the animal model
of AMD (Figure 4 and Table 4B). In fact, in AMD patients the
TGF-β (p = 4 E-7) and prion diseases (p = 1 E-6) pathways
were top scored, along with lipid metabolism, neurodegenerative
and inflammatory pathways. Interestingly, the VEGF pathway
(p = 3 E-2) was found to be targeted only by the set of miRNAs
dysregulated in serum of AMD patients (Table 4B).
Analysis of serum of Aβ-injected rats revealed that one
miRNA out of 13, miR-155 was down-regulated in comparison
to control rats, similarly to what was found in serum of AMD
patients. We have looked at pathways that can be associated to
miR-155 (Table 4C). The miR-155 can regulate genes involved
in the TGF-β signaling pathway (p = 4 E-4), in the apoptosis
pathway (p = 1 E-3) and several inflammatory pathways, that
are also regulated by the set of miRNAs differentially expressed
in Aβ-injected rats and in AMD patients.
DISCUSSION
Thirteen miRNAs (Table 1) have been selected on the basis of
previous reports on their role in AD and AMD. Analysis of these
13 miRNAs revealed that 7 miRNAs showed a significant up-
regulation in serum of AMD patients in comparison to control
group (miR-9, miR-23a, miR-27a, miR-34a, miR-146a, miR-155,
and miR-126). Three miRNAs were found to be dysregulated
both in AMD patients and in retina of Aβ-injected rats (miR-
27a, miR-146a, miR-155). Incidentally, we showed that changes
in circulating levels of some miRNAs (miR-9, miR-23a, miR-
27a, miR-34a, miR-126, miR-146a, miR-155) as found in AMD
patients are associated to Alzheimer’s disease andmodulate genes
involved in neurodegenerative and inflammatory pathways.
In accordance to the finding of Ménard et al. (2016), we
found that miR-146a is up-regulated in plasma of AMD patients
and in the retina of Aβ-injected rats; furthermore this miRNA
is dysregulated also in AD patients (Kiko et al., 2014; Müller
et al., 2014; Denk et al., 2015; Ménard et al., 2016). To our
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FIGURE 1 | Box Plots of miRNAs in rat retina. Values on the y-axis are
reported as –1Ct. *p < 0.05, **p < 0.01 vs. control.
TABLE 3 | Fold-changes (FC) of miRNA expression in AMD patients vs.
control group (healthy subjects).
miRNA P-value FC
miR-9 0.006 6.47
miR-21 0.065
miR-23a 0.006 2.11
miR-24 0.06
miR-27a 0.004 4.13
miR-30b 0.274
miR-34a 0.007 3.28
miR-125b 0.626
miR-126 0.019 2.97
miR-146a 0.001 1.46
miR-146b 0.124
miR-155 0.021 −5.09
miR-210 0.070
knowledge, dysregulation of miR-27a has not been reported by
other authors before, neither in experimental animal models nor
in in vitro models of AMD. Wang et al. (2012) suggested for the
FIGURE 2 | Box Plots of miRNAs commonly dysregulated in AD and
AMD patients. Values on the y-axis are reported as −1Ct. *p < 0.05, **p <
0.01 vs. control.
first time the potential role of miR-27a in AMD. Furthermore,
involvement of miR-27 in AD was well documented by other
authors (Maes et al., 2009; Sala Frigerio et al., 2013). We found
down-regulation of miR-155 in serum of AMD patients and Aβ
injected rats; whereas we found up-regulation of miR-155 in the
retina of Aβ injected rats, along with miR-27a and miR-146a.
Our results are in accordance to the report by Guedes et al.
(2014), showing the up-regulation of miR-155 in hippocampal
and cortical brain regions of 3-Tg AD animals as well as in
cultured microglia and astrocytes treated with Aβ oligomers.
Because miR-155 is associated to blood brain barrier dysfunction
(Lopez-Ramirez et al., 2014), the up-regulation of miR-155 in
retina of rats injected with Aβ oligomers might also influence
the integrity of blood retinal barrier (BRB). MiR-155 and its
angiogenic target gene CCN1 were found to alter vascular and
neovascular growth in mice retina (Berber et al., 2017). Increased
expression of miR-155 induced formation of neovascular tufts
that growth abnormally in vitreous with concomitant retinal
microglial activation (Yan et al., 2015); thus, up-regulation of
miR-155 in retina of Aβ injected rats might be the triggering
factor of retinal inflammation and pro-angiogenic events. We
found an increased expression of miR-155 in rat retina 72 h after
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FIGURE 3 | Scatter distribution of pathways regulated by miR-27a,
miR-146a, and miR-155. Solid spheres correspond to predicted pathways.
Blue (dark gray in the print version) points are the projections of # of genes, red
(gray in the print version) points are the projections # of microRNA, and green
(light gray in the print version) points are the projections of p-value associated
to each pathway. (NT, neurotrophin signaling pathway; TNF, TNF signaling
pathway; HIF, hypoxia inducible factor pathway).
intravitreal injection of Aβ oligomers; this result is in agreement
with a previous work by Saxena et al. (2015), who found increased
levels of miR-155 in retina of rats 72 h after light-induced retinal
damage.
With exception of miRNA-155, down-regulated in serum
of AMD patients and in serum of Aβ injected rats, six
miRNAs (miR-9, miR-23a, miR-27a, miR-34a, miR-146a, miR-
126) showed an up-regulation in serum of AMD patients. Lack
of differentially expressed circulating miRNAs in serum of Aβ-
injected rats, other than down-regulated miR-155, could be
related to variables that characterize miRNA secretion such as
aging, duration and type of pathology (Creemers et al., 2012;
Weilner et al., 2013).
Overall, results obtained by our translational approach
reinforce the hypothesis of a link between AMD and AD
and further validate the retinal degenerative model induced by
intravitreal injection of Aβ oligomers (Fisichella et al., 2016).
In order to study the biological role of the miRNAs
dysregulated in retina of Aβ-injected rats and in serum of
AMD patients, we have predicted the combinatorial effects of
miRNAs in regulation of biological relevant pathways by means
of DIANA-miRPath v.3. GivenmiRNAs as input, Diana-miRPath
gives as output the KEGG (Kyoto Encyclopedia of Genes and
Genomes) pathways potentially regulated by genes targeted by
input miRNAs. We found that miRNAs, dysregulated both in
serum of AMD patients and retina of Aβ-injected rats, can
target genes of pathways associated to neurodegenerative diseases
(e.g., apoptosis, ubiquitin proteolysis, neurotrophin signaling)
along with inflammatory signaling pathways (e.g., mTOR, HIF,
TABLE 4 | KEGG pathways target of miRNAs potentially deregulated in
AMD.
A. miR-27a, miR-146a, miR-155 p-value #genes
TGF-beta signaling pathway 1.31E-11 44
Prion diseases 2.90E-11 14
Hippo signaling pathway 2.53E-7 60
AMPK signaling pathway 1.16E-6 62
Fatty acid biosynthesis 1.50E-6 3
Fatty acid elongation 7.45E-6 9
Lysine degradation 7.73E-6 22
Neurotrophin signaling pathway 8.25E-6 58
mTOR signaling pathway 2.61E-5 35
Protein processing in endoplasmic reticulum 2.65E-5 73
TNF signaling pathway 3.20E-5 51
Fatty acid metabolism 5.17E-5 16
Signaling pathways regulating pluripotency of stem cells 5.17E-5 62
FoxO signaling pathway 5.78E-5 60
Thyroid hormone signaling pathway 6.42E-5 48
Adherens junction 1.61E-4 36
Ubiquitin mediated proteolysis 3.12E-4 62
Central carbon metabolism in cancer 3.12E-4 30
HIF-1 signaling pathway 9.92E-4 51
ErbB signaling pathway 2.38E-3 39
Sphingolipid signaling pathway 2.67E-3 48
Focal adhesion 3.26E-3 81
Insulin signaling pathway 4.31E-3 58
NF-kappa B signaling pathway 4.31E-3 32
Apoptosis 4.68E-3 38
Cell cycle 9.58E-3 50
PI3K-Akt signaling pathway 1.18E-2 121
ECM-receptor interaction 1.68E-2 26
p53signaling pathway 2.16E-2 30
Toll-like receptor signaling pathway 2.33E-2 39
Axon guidance 3.13E-2 43
RNA transport 3.38E-2 62
Endocytosis 4.53E-2 72
B. miR-9, miR-23a, miR-27a, miR-34a,
miR-126,miR-146a, miR-155
p-value #genes
Fatty acid metabolism 3.15E-1 30
Fatty acid elongation 8.96E-3 14
Fatty acid degradation 2.02E-4 24
Adherens junction 3.86E-3 53
TGF-beta signaling pathway 4.74E-4 56
Fatty acid biosynthesis 8.23E-4 7
Thyroid hormone signaling pathway 9.39E-3 84
Protein processing in endoplasmic reticulum 9.39E-3 114
Prion diseases 1.09E-5 21
p53 signaling pathway 8.77E-5 54
mTOR signaling pathway 2.91E-6 47
Hippo signaling pathway 4.40E-6 90
Neurotrophin signaling pathway 5.23E-6 82
TNF signaling pathway 7.93E-5 74
(Continued)
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TABLE 4 | Continued
B. miR-9, miR-23a, miR-27a, miR-34a,
miR-126,miR-146a, miR-155
p-value #genes
Cell cycle 1.18E-4 83
Endocytosis 1.28E-4 130
Signaling pathways regulating pluripotency of stem cells 1.58E-4 90
Sphingolipid signaling pathway 4.27E-4 76
ErbB signaling pathway 5.24E-4 62
Lysine degradation 7.50E-4 31
Axon guidance 8.49E-4 78
Estrogen signaling pathway 8.68E-4 63
Insulin signaling pathway 1.04E-3 91
Focal adhesion 1.07E-3 128
FoxO signaling pathway 1.06E-3 88
Ubiquitin mediated proteolysis 2.08E-3 89
HIF-1 signaling pathway 2.21E-3 72
Glycosaminoglycan biosynthesis - keratansulfate 2.64E-3 11
Regulation of actin cytoskeleton 4.51E-3 123
Apoptosis 5.05E-3 57
AMPK signaling pathway 7.36E-3 80
N-Glycan biosynthesis 1.41E-2 30
RNA degradation 2.41E-2 49
Fc gamma R-mediated phagocytosis 2.69E-2 55
NF-kappa B signaling pathway 2.69E-2 52
VEGF signaling pathway 3.02E-2 40
C. miR-155 p-value #genes
TGF-beta signaling pathway 4.69E-4 11
FoxO signaling pathway 4.69E-4 26
Apoptosis 1.29E-3 20
Steroid biosynthesis 2.13E-3 4
NF-kappa B signaling pathway 2.13E-3 17
TNF signaling pathway 2.14E-3 22
Inflammatory bowel disease (IBD) 4.66E-3 13
Adherens junction 9.67E-3 14
Fatty acid elongation 1.13E-2 4
Signaling pathways regulating pluripotency of stem cells 1.19E-2 25
TNFα, and VEGF signaling; Figures 3, 4). Furthermore, TGF-β
signaling was one of the top scored pathways along with prion
diseases pathway. Dysregulation of TGF-β pathway in AD and
the protective role of TGF-β1 toward brain neuroinflammatory
processes were previously reported (Caraci et al., 2008, 2011,
2015; Chen et al., 2015). Furthermore, we have previously found
that TGF-β1 administration can revert the increase in Bax/Bcl2
ratio induced in rat retina following intravitreal administration
of Aβ oligomers (Fisichella et al., 2016).
Thus, we postulate that Aβ retinal deposition leads to
inflammatory and apoptotic events along with differential
expression of miRNAs able to target genes, which, in
turn, dysregulate the TGF-β pathway. In fact, miR-155 and
miR-27a can target 42 genes involved in the TGF-β pathway
(DIANA-miRPath), while miR-146a can target genes involved
in inflammatory pathways (Toll-like receptor, NF-κB, TNF
FIGURE 4 | Scatter distribution of pathways associated to miRNAs that
are dysregulated in serum of AMD patients. Solid spheres correspond to
predicted pathways. Blue (dark gray in the print version) points are the
projections of # of genes, red (gray in the print version) points are the
projections # of microRNA, and green (light gray in the print version) points are
the projections of p value associated to each pathway. (NT, neurotrophin
signaling pathway; TNF, TNF signaling pathway; HIF, hypoxia inducible factor
pathway; VEGF, vascular endothelial growth factor).
signaling pathways). Worthy of note, three KEGG pathways
were more recurrent: prion diseases, TGF-beta signaling, insulin
receptor signaling; such bioinformatics data reinforce the link
between AMD and AD. Finally, miRNAs dysregulated both in
AMD patients and in rat retina damaged by Aβ can target the
TGF-β signaling pathway, leading to a putative impairment of
Smad-dependent TGF-β1 signaling, in accordance with previous
reports (Caraci et al., 2012a,b; Fisichella et al., 2016).
CONCLUSION
In conclusion, the modified miRNA levels we found in rat retina
(miR-27a, miR-146a, miR-155) and serum of AMD patients
(miR-9, miR-23a, miR-34a, miR-126, miR-27a, miR-146a, miR-
155) suggest that, among others, miR-27a, miR-146a, and miR-
155 have an important role in AMD and could represent suitable
biomarkers and appealing pharmacological targets.
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